⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5984389 | 1.00 | — | — | |
| SCHEMBL83365 | 0.88 | — | — | |
| SCHEMBL83366 | 0.88 | — | — | |
| SCHEMBL1677758 | 0.84 | — | — | |
| SCHEMBL1677761 | 0.84 | — | — | |
| SCHEMBL930495 | 0.82 | — | — | |
| SCHEMBL2496645 | 0.82 | FAAH (0.31) | — | |
| SCHEMBL18632159 | 0.82 | — | — | |
| SCHEMBL930494 | 0.82 | — | — | |
| SCHEMBL1617441 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197724-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | NIPPON SHINYAKU CO., LTD. (JP) | 2024-06-20 | — | — | US | disclosed |
| EP-4316489-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | Nippon Shinyaku Co., Ltd. (JP) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023234426-A1 | ANTIBODY-MULTIDRUG CONJUGATE | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| WO-2023234427-A1 | ANTIBODY-MULTIDRUG CONJUGATE PRECURSOR AND SYNTHETIC INTERMEDIATE THEREOF | ＵＢＥ株式会社 | 2023-12-07 | — | — | WO | disclosed |
| CN-117157075-A | Remedies for gait disorder | 日本新药株式会社 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023163227-A1 | ANTIBODY-DRUG CONJUGATE | ＵＢＥ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023163234-A1 | ANTIBODY-DRUG CONJUGATE PRECURSOR AND INTERMEDIATE FOR SYNTHESIS THEREOF | ＵＢＥ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2022211052-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | 日本新薬株式会社 | 2022-10-06 | — | — | WO | disclosed |
| EP-3386473-B1 | OLIGOESTER AMMONIUM SALTS AND THEIR USE IN COSMETIC COMPOSITIONS | CLARIANT INT LTD (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-4992455-A | Cardiovascular disorders | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-02-12 | — | — | US | disclosed |
| EP-0314435-A2 | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition, processes for their preparation and compositions containing them | Sankyo Company Limited (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0292305-A1 | Novel thiazolidin-4-one derivatives and acid addition salts thereof | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1988-11-23 | — | — | EP | disclosed |
| US-4782160-A | CALCIUM RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0276552-A1 | 1,4-dihydropyridine derivatives and their production | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-03 | — | — | EP | disclosed |
| US-4584265-A | TRIAZINE COMPOUNDS SUBSTITUTED WITH STERICALLY HINDERED PHENOL=ANDPOLYALKYLPIPERIDINE GROUPS | CIBA-GEIGY AG (CH) | 1986-04-22 | — | — | US | disclosed |
| US-4558131-A | PHOTOSTABILIZERS | CIBA-GEIGY AG (CH) | 1985-12-10 | — | — | US | disclosed |
| EP-0138767-A1 | Stabilized polyolefinic compounds containing hydroxylamine derivatives | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | disclosed |
| US-4357446-A | CROSSLINKING AGENT IS 2,3-DIMERCAPTO-PYRAZINE OR-QUINOXALINE | OSAKA SODA CO. LTD. (JP) | 1982-11-02 | — | — | US | disclosed |
| US-4234705-A | 3,5-DIMERCAPTO-1,2,4-TRIAZOLES | OSAKA SODA CO. LTD. (JP) | 1980-11-18 | — | — | US | disclosed |